Bonefos Approval Contingent On Study Results Expected In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will not approve the breast cancer bone metastases treatment before seeing confirmatory efficacy results from the National Surgical Adjuvant Breast & Bowel Project B-34 study. The drug was deemed "approvable" in January.
You may also be interested in...
Zometa Jaw Bone Death Awareness Program Should Be Enhanced – Cmte.
FDA's Oncologic Drugs Advisory Committee recommends that distribution of Novartis' "Dear Doctor" letter for Zometa and Aredia be extended to include dentists. Aggressive promotion of the bisphosphonates should also be curtailed, committee members suggest.
Berlex’ Bonefos “Approvable”
Berlex' oral non-amino bisphosphonate Bonefos (clodronate) is "approvable" at FDA for breast cancer bone metastases
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.